Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caffeine + albuterol is a combination of two small molecule drugs, caffeine and albuterol. Caffeine is a central nervous system stimulant that acts primarily as an adenosine receptor antagonist, increasing alertness and metabolic rate. Albuterol (also known as salbutamol) is a selective beta-2 adrenergic receptor agonist used primarily for bronchodilation in asthma and chronic obstructive pulmonary disease (COPD). The combination has been investigated for synergistic effects on body composition, specifically to reduce fat mass and increase lean body mass, with potential applications in obesity and sarcopenia. The rationale for the combination includes both agents' ability to stimulate metabolism and promote lipolysis or muscle growth through different mechanisms[5][6]. There are no widely marketed products containing this exact combination; its use remains investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + albuterol.